Form D · Biotechnology

Propagenix Inc.

Gaithersburg, MD · CIK 0001605963

Offering snapshot reported Mar 31, 2016 · SEC filing

Reported sold: $6.5M
Investors reported: 2
Minimum accepted: $0
First sale: Mar 18, 2016

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$2,300,000 → $6,500,000
Reported investors1 → 2

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 31, 2016	Amendment	$6,500,000	$4,200,000vs Apr 23, 2014	2	SEC filing
Apr 23, 2014	Initial	$2,300,000	No comparison	1	SEC filing

Offering details

Securities: Equity, Other
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-216099

Offer and sale of Series A Preferred Stock, and the underlying shares of Common Stock issuable upon conversion thereof.

Source: Form D, filed Mar 31, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Greg Betterton	Director
Sharon Challberg	Executive
John Kontor	Director
Wlodek Krawiec	Director
Edward Maker	Director
Brian Pollok	Director, Executive
David Ross	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

20641 Plum Creek Court
Gaithersburg, MD, 20882